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Eradication of H. pylori infection heals type B chronic
active gastritis, peptic ulcer disease, and virtually abol-
ishes ulcer recurrence. Cure of the infection also results
in a complete histological regression of gastric MALT
lymphoma in 80% of the patients and prevents recur-
rence in almost all cases and may prevent metachronous
occurrence of gastric adenocarcinoma following endo-
scopic resection of early gastric cancer. Recommenda-
tions for eradication treatment from major consensus con-
ferences include all patients with H. pylori associated
DU or GU and patients with a previously confirmed ul-
cer on continuous antisecretory maintenance therapy,
patients who present with H. pylori associated ulcer
bleeding, and patients with gastric MALT lymphoma.
There is no evidence currently to support the routine
treatment of H. pylori infection in all patients with non-
ulcer dyspepsia and this is recommended only on a case
by case basis. However, most consensus groups have
acknowledged that patients with undiagnosed dyspep-
sia, in the primary care setting under the age of 45 years
of age and without alarm symptoms, may benefit.
After more than a decade of trial and error, treat-
ment to eradicate the infection has evolved from an ini-
tial approach, using complex bismuth based therapies, to
current standard triple therapies consisting of a proton
pump inhibitor, clarithromycin and amoxicillin or metron-
idazole on the basis of simplicity, safety and efficacy.
This approach has been endorsed by consensus confer-
ences in Europe, North America, and in the Asia Pacific
region in 1996-1998. The recommendations have been
based on numerous large randomized controlled clinical
trials that consistently have achieved an eradication rate
of > 80% by intent-to-treat analysis and > 90% by per-
protocol analysis. In an extensive analysis of the litera-
ture, we have identified several factors determining the
success of H. pylori eradication treatment. They include
the components of a treatment regimen, the treatment
duration, patient compliance, the presence of resistant
or virulent strains of H. pylori, and possibly the patient’s
gastric acid secretory status. In a meta-analysis of 82
studies involving 110 treatment arms and 6123 patients,
we have shown that clarithromycin at a dose of 500 mg
bid was significantly more effective than 250 mg bid when
given with a PPI and amoxicillin for 7 days by intent-to-
treat analysis (86.6% vs 78.2%, p<0.0001). The eradi-
cation rates achieved with PPI twice daily were signifi-
cantly higher than PPI once daily regimens. Bacterial
resistance to clarithromycin and metronidazole plays an
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important role in determining the success of H. pylori
eradication treatments. There is a good correlation be-
tween bacterial resistance to clarithromycin and treat-
ment failure; however, the clinical relevance of H. py-
lori resistance to nitroimidazoles detected in vitro has
been controversial, especially in studies using the PMC
combination. We have performed a meta-analysis of 44
treatment arms and 3084 patients treated with three dif-
ferent PPI-based triple therapies. The efficacy of PMC
and PAM combinations was significantly reduced in the
presence of metronidazole resistance, whereas, the ef-
ficacy of PAC regimen was not affected. When treat-
ments were given to patients harboring metronidazole-
sensitive strains of H. pylori, the eradication rates, by
intent-to-treat analysis, were 93% for 7-day PMC, 92%
for 7-day PAM, and 90% for 10-14-day PAM regimens,
respectively. However, in the presence of metronida-
zole resistance, the efficacy was reduced by 14%, 41%,
and 24%, respectively. Based on these results, we de-
veloped a model to predict the likelihood of treatment
failure for the PMC and PAM regimens in the presence
of metronidazole resistance with the PAC regimen as a
reference. When metronidazole resistance exists, the
relative risks of treatment failure increases by 2.2, 4,
and 7.9-fold when patients are treated with the 7-day
PMC, 10-14-day PAM, and 7-day PAM, respectively.
The results indicate that metronidazole-containing regi-
mens should be avoided when metronidazole resistance
is suspected or proven. Indeed, it is recommended that
PPI combinations with clarithromycin and metronidazole
should not be used as first choice treatment since this
utilizes the two most effective antibiotics for H. pylori
infection together and failure with this regimen will make
it much harder to eradicate the infection subsequently.
More recently, treatment combinations consisting of
RSC, clarithromycin and amoxicillin or metronidazole
given for 7 days have provided similar efficacy to PPI-
based triple therapies for H. pylori eradication treat-
ment. However, the lack of availability and relatively high
cost of RBC limits its wide use.
To overcome the impact of bacterial resistance on
the efficacy of eradication treatments, several newer
agents such as furazolidone and rifabutin have been used
as a substitute for metronidazole in bismuth-or PPI-based
triple therapies in regions where the prevalence of met-
ronidazole resistant strains is high. These combination
treatments have shown promising results. However, com-
pared to the currently recommended PPI-triple thera-
pies, treatment-related adverse events are common,
which can lead to high drop-out rates.
Esomeprazole (E), the new optical isomer of
omeprazole, may provide more effective and predict-
able control of intragastric pH than existing PPIs. When
given with amoxicillin and clarithromycin, EAC has been
shown to be as effective as OAC for eradicating H.
pylori infection in several comparative thals.
Bismuth based triple therapies are the oldest, least
expensive, but highly effective treatment regimens for
eradication of H. pylori infection. When used in PPI-
quadruple therapies, high and consistent eradication rates
can be achieved. However, the complexity of adminis-
tration and poor patient compliance have limited its ac-
ceptance. Recently, a single capsule, containing colloi-
dal bismuth subcitrate 40 or 60 mg (B), metronidazole
125 mg (M), and tetracycline 125 mg (T), has been de-
veloped and proven to be highly effective, when given
with a PPI (or alone), for eradicating H. pylori infection
in two studies, with eradication rates of greater than 85%
by intent-to-treat analysis.
In conclusion, treatment to eradicate H. pylori in-
fection has become the mainstay of care for treating
patients with H. pylori associated peptic ulcer disease,
chronic active gastritis, and gastric MALT lymphoma.
Treatment regimens consisting of a PPI at the recom-
mended dose, clarithromycin 500 mg, amoxicillin 1 g, or
metronidazole 400 mg, all given bid for 7 days, are the
most commonly used combination regimens. However,
in the US, the recommended treatment duration is 10 to
14 days. RBC-based triple therapies, furazolidone or
rifabutin containing regimens can be used as an alterna-
tive approach to PPI-based triple therapies in areas where
bacterial resistant strains of H. pylori are concerned.
Preliminary results with the newly developed BMT single
capsule triple therapy are promising, however, large clini-
cal trials are needed to compare its efficacy with the
currently recommended PPI-based triple therapies. Since
the management of treatment failures has become a chal-
lenging issue and secondary bacterial resistance mainly
result from previous treatment failure, the most effec-
tive treatment regimen should always be used as the
first line treatment choice to minimize the occurrence of
treatment failure. This is a PPI with amoxicillin and
clarithromycin.
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